Oncospire Genetics

OncoSpire Genomics was a cancer diagnostics joint venture formed in 2013 by Mayo Clinic and Cancer Genetics to discover and commercialize oncology tests based on next-generation sequencing and biomarker research. The company focused on targeted molecular diagnostic panels intended to provide clinically actionable information in areas of unmet need in oncology. Public disclosures identified early programs in lung cancer, multiple myeloma, and follicular lymphoma, and Cancer Genetics later said an NGS panel for multiple myeloma had been launched for clinical-trial use with plans for routine clinical use. Available third-party company directories indicate the venture is no longer active.